NCT06693726

Early Angiotensin II in the Emergency Department

ANGIOtensin II for Septic Shock in the Emergency Department: ANGIO-ED Study

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Brett A Faine · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED

Detailed description

Following informed consent, patients will receive intravenous angiotensin II (AT-II) infusion for blood pressure support. The patient will remain on the AT-II infusion for 60 minutes prior to determining patient response which will be determined by recording the concurrent dose of norepinephrine and MAP every 10 minutes from initiation. If a positive response (e.g., norepinephrine dose reduction) is witnessed, the AT-II infusion will be titrated off after a maximum of 6 hours or when infusion is completed, whichever occurs first.

Conditions

• Septic Shock

Interventions

Type	Name	Description
DRUG	Angiotensin II Infusion	Angiotensin II continuous infusion

Timeline

• Start date: 2025-04-01
• Primary completion: 2026-08-31
• Completion: 2026-11-30
• First posted: 2024-11-18
• Last updated: 2026-03-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study